Drug intelligence / Profile preview

NMT.004

Development stage: Preclinical
Lead developer: Neumirna Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

NMT.004 is an antisense oligonucleotide (ASO) drug candidate developed by Neumirna Therapeutics ApS, currently in preclinical development for the treatment of epilepsy and other nervous system diseases. The specific molecular target and mechanism of action have not been publicly disclosed, but as an ASO, it is designed to modulate gene expression at the RNA level, likely by binding to a specific mRNA sequence involved in disease pathology[1]. No clinical trial data or additional indications are available at this time.

Beyond the preview

Go deeper on NMT.004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMT.004.

Explore the full profile